A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Trial Profile

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Naproxen sodium/sumatriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Jun 2012 Results were reported in Headache.
    • 23 Feb 2010 Actual number of patients (173), actual end date (Dec 2007) as reported by ClinicalTrials.gov.
    • 20 Aug 2008 Status changed from recruiting to completed, as reported on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top